Gemcitabine/Cisplatin
- Generic Name
- Gemcitabine/Cisplatin
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT06109779
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT03601975
- Locations
- 🇨🇳
651 Dongfeng Road East, Yuexiu District, Guanzhou, P.R. China, Guangzhou, Guangdong, China
Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
- Conditions
- Upper Tract Urothelial Carcinoma
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- The European Uro-Oncology Group
- Target Recruit Count
- 200
- Registration Number
- NCT02969083
- Locations
- 🇪🇸
Hospital Clinico de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitari de Girona Doctor Josep Trueta, Gerona, Spain
🇪🇸Hospital Complex Insular-Materno Infantil, Las Palmas, Spain
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- Drug: Docetaxel/OxaliplatinDrug: Docetaxel/CarboplatinDrug: Gemcitabine/CarboplatinDrug: Placebo
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 500
- Registration Number
- NCT02889666
- Locations
- 🇨🇳
China-Japan Union Hospital, Jilin University, Changchun, Jilin, China
🇨🇳Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
🇨🇳Shanghai 10th People's Hospital, Shanghai, China
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: Gemcitabine/Cisplatin /S-1
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Kansai Hepatobiliary Oncology Group
- Target Recruit Count
- 246
- Registration Number
- NCT02182778
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Gemcitabine, Docetaxel, CPT-11,Cisplatin
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Tongji University
- Target Recruit Count
- 120
- Registration Number
- NCT01424709
- Locations
- 🇨🇳
Medical Department, Shanghai Pulmonary Hospital, Shanghai, China
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 72
- Registration Number
- NCT01407822
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- Drug: Docetaxel/Cisplatin controlDrug: Docetaxel/Cisplatin
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 500
- Registration Number
- NCT00478699
- Locations
- 🇪🇸
Hospital de Elche, Elche, Alicante, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Ico - H. Germans Trias I Pujol, Badalona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.